Bank of New York Mellon
CMPX icon

Bank of New York Mellon’s Compass Therapeutics CMPX Stock Holding History

Bank of New York Mellon’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$769K Buy
351,032
+53,731
+18% +$159K ﹤0.01% 3513
2026
Q1 		$1.57M Sell
297,301
-15,179
-5% -$87.6K ﹤0.01% 2944
2025
Q4 		$1.68M Buy
312,480
+89,304
+40% +$412K ﹤0.01% 2943
2025
Q3 		$781K Buy
223,176
+11,993
+6% +$37.9K ﹤0.01% 3354
2025
Q2 		$549K Sell
211,183
-32,382
-13% -$66.8K ﹤0.01% 3461
2025
Q1 		$463K Buy
243,565
+5,590
+2% +$14.9K ﹤0.01% 3486
2024
Q4 		$345K Buy
237,975
+6,041
+3% +$10K ﹤0.01% 3701
2024
Q3 		$427K Sell
231,934
-52,004
-18% -$64.8K ﹤0.01% 3600
2024
Q2 		$284K Buy
283,938
+31,433
+12% +$45.9K ﹤0.01% 3837
2024
Q1 		$500K Sell
252,505
-18,659
-7% -$32.2K ﹤0.01% 3528
2023
Q4 		$423K Sell
271,164
-1,288
-0.5% -$2.23K ﹤0.01% 3646
2023
Q3 		$537K Buy
272,452
+1,156
+0.4% +$2.86K ﹤0.01% 3506
2023
Q2 		$863K Buy
271,296
+231,990
+590% +$728K ﹤0.01% 3289
2023
Q1 		$129K Hold
39,306
– – ﹤0.01% 4030
2022
Q4 		$198K Buy
39,306
+15,055
+62% +$60K ﹤0.01% 3974
2022
Q3 		$55K Buy
+24,251
New +$67.1K ﹤0.01% 4304

Other funds holding CMPX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Bank of New York Mellon's CMPX Position: Q2 2026 in Review

Bank of New York Mellon increased its Compass Therapeutics (CMPX) stake by 18% in Q2 2026, buying an estimated $159K and bringing the position to 351,032 shares worth $769K. The position accounts for ﹤0.01% of the portfolio, ranked #3513.

Bank of New York Mellon first reported a position in CMPX in Q3 2022 and has held it in 16 quarters since. The position peaked at $1.68M in Q4 2025. 63 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Bank of New York Mellon held 351,032 shares of Compass Therapeutics worth $769K as of Q2 2026.
  • Bank of New York Mellon bought 53,731 Compass Therapeutics shares in Q2 2026, an estimated $159K.
  • Compass Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3513 holding.
  • Bank of New York Mellon first reported a position in Compass Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Bank of New York Mellon's Compass Therapeutics position peaked at $1.68M in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.